Page 837 - Read Online

Franco et al. Hepatoma Res 2018;4:74 I http://dx.doi.org/10.20517/2394-5079.2018.94 Page 11 of 18

DECLARATIONS
Authors’ contributions
Design, literature research, manuscript writing: Franco RA
Manuscript editing: Galbraith JW, Overton ET
Manuscript revision: Saag MS

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Franco RA is has served as a consultant to Gilead and Bristol Myers-Squibb and is an investigator on grants
paid to his institution from Gilead, Merck and Janssen; Galbraith JW has served on Gilead and AbbVie ad-
visory boards and received grants from Gilead Sciences paid to his institution; Overton ET receives research
support for the National Institute of Health, Gilead, Merck and Abbvie paid to his institution and has served
as a consultant to Gilead and ViiV; Saag MS is a scientific advisor to Gilead, Merck, and ViiV, and principal
investigator on grants paid to his institution from Gilead, Merck, and ViiV.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a
modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus
infection. J Hepatol 2014;61:S45-57.
3. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, et al. The global burden of viral hepatitis from 1990 to 2013: findings
from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8.
4. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
5. Freeman AJ, Marinos G, Ffrench RA, Lloyd AR. Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 2001;79:515-36.
6. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, et al. Eradication of hepatitis C virus in patients successfully
treated for chronic hepatitis C. Gastroenterology 2008;135:821-9.
7. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights
from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408-14.
8. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, et al. The new paradigm of hepatitis C therapy: integration of oral
therapies into best practices. J Viral Hepat 2013;20:745-60.
9. WHO. Global health sector strategies on viral hepatitis 2016-2021. Available from: https://www.who.int/hepatitis/strategy2016-2021/
ghss-hep/en/. [Last accessed on 28 Nov 2018]
10. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1.
N Engl J Med 2012;366:216-24.
11. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, et al. Isolation of a cDNA clone derived from a bloodborne non-A, non-B
viral hepatitis genome. Science 1989;244:359-62.
12. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997; 25:1527-38.
13. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell
line. Science 1999;285:110-3.
14. Götte M, Feld JJ. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol
2016;13:338-51.